Axsome Therapeutics, Inc.

$156.28

$2.60(-1.64%)

Axsome Therapeutics, Inc.

AXSM

$156.28

$2.60(-1.64%)

Axsome Therapeutics, Inc.

AXSM

NASDAQ

$156.28

$2.60(-1.64%)

Chart

Upcoming Earnings

Next report date

May 4, 2026

Report period

Q2 2026

EPS Estimate

$-0.78

Revenue Estimate

$195.13M

Key stats

52-Week Range$156.28

$86.99

$191.50

Market capitalization

$8.09B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-45.98

Basic EPS (TTM)

$-3.69

Net income (TTM)

$-183.17M

Revenue (TTM)

$638.50M

Avg. volume

685.58K

Beta (1Y)

0.49

Employees

712

Market capitalization

$8.09B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-45.98

Basic EPS (TTM)

$-3.69

Net income (TTM)

$-183.17M

Revenue (TTM)

$638.50M

Avg. volume

685.58K

Beta (1Y)

0.49

Employees

712

Screener Quick Check

About Axsome Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

CEO

Herriot Tabuteau

Website

www.axsome.com

Headquarters

22 Cortlandt Street, New York City, NY, 10007

IPO Date

2015-11-19

Identifiers

ISINUS05464T1043

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous...

Related Stocks

Jazz Pharmaceuticals plc

JAZZ

$182.02Mkt Cap: $11.21B

Healthcare

Biotechnology

ISIN:IE00B4Q5ZN47

Abivax S.A.

ABVX

$122.75Mkt Cap: $8.05B

Healthcare

Biotechnology

ISIN:US00370M1036

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate